ArticleJournal of thoracic disease2026
Radiomics differences between GOLD I-II and GOLD III-IV in patients with chronic obstructive pulmonary disease.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-resolution computed tomography (HRCT) serves as an effective imaging modality for characterizing and quantifying structural lung changes associated with chronic obstructive pulmonary disease (COPD). The emerging field of radiomics enables the rapid extraction of numerous quantitative features from medical images, offering considerable promise for supporting clinical decisions. Therefore, the aim of this study was to explore the lung function-associated radiomics features in COPD patients. Methods: This cross-sectional study enrolled 223 patients diagnosed with COPD. The final study cohort comprised 94 patients classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I-II and 56 as GOLD stage III-IV. For all participants, baseline demographic and clinical characteristics, spirometry data, and chest HRCT images were collected. Subsequently, 944 quantitative radiomics features were extracted from each HRCT scan. To identify features associated with GOLD stages, we employed least absolute shrinkage and selection operator (LASSO) regression for feature selection, followed by logistic regression for modeling. Finally, a nomogram along with its validation curves was constructed to visualize and assess the performance of the predictive model. Results: Following feature selection via LASSO regression, eight potential predictors were retained. Subsequent binary logistic regression refined this set, revealing two radiomics features (original_firstorder_10Percentile and wavelet.LHL_glszm_GrayLevelVariance) that were independently associated with GOLD stages. The model's discrimination was validated by a C-index of 0.838 and an area under the receiver operating characteristic curve (AUC) of 0.820. Furthermore, decision curve analysis (DCA) confirmed the clinical utility of the nomogram, showing a positive net benefit for decision thresholds from 0.13 to 0.84. Conclusions: Collectively, a noticeable difference in radiomics features was observed between GOLD I-II and GOLD III-IV patients with COPD. The computed tomography (CT)-based radiomics features, original_firstorder_10Percentile and wavelet.LHL_glszm_GrayLevelVariance, can be potentially used to evaluate the severity of COPD patients. However, our results require further validation through multicenter and large-scale clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.